Beijing Chieftain Control Engineering Technology (300430.SZ) plans to pay 0.55 yuan per 10 shares in 2023, with ex-dividend and ex-rights on July 9.

Chieftain Control Engineering Technology (300430.SZ) announced on the Smart Finance and Economics App that the company plans to distribute cash dividends of RMB 0.55 per 10 shares to all shareholders in 2023, with the record date on July 8, 2024 and the ex-dividend date on July 9, 2024.

Zhitong FinanceJul 2 08:57 ET

Chengyitong (300430.SZ): The core product automated biological fermentation control system has many applications in the field of synthetic biology

Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Are there synthetic biological-related technologies currently being developed by the company?” The company replied that downstream customers in the company's intelligent manufacturing sector mainly include pharmaceutical and biological manufacturing companies. Biomaneling is mainly a production method using synthetic biotechnology as an important technical support and biological fermentation process as an important means of implementation. The company's core product, the automated biological fermentation control system, has many applications in the field of synthetic biology. Driven by synthetic biotechnology and green biological manufacturing, 202

Gelonghui FinanceMay 9 04:44 ET

Chengyitong (300430.SZ): Currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of invasive technology

Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Can the brain-computer products the company is developing regenerate insulin to treat diabetes?” The company replied that currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of intrusive technology. In planning non-invasive technology, the company integrates existing rehabilitation products with brain-computer interfaces to achieve product upgrades, thereby providing more effective rehabilitation services for patients with neurological diseases. In the future, the company will also focus on the application of brain-computer interfaces in other medical fields

Gelonghui FinanceMay 9 04:41 ET

Chengyitong (300430.SZ) announced first-quarter results, net profit of 307.813 million yuan, an increase of 37.71%

Chengyitong (300430.SZ) released its report for the first quarter of 2024, achieving 2.68 operating income during the reporting period...

Zhitong FinanceApr 28 04:15 ET

Chengyitong (300430.SZ) issued 2023 annual results, with net profit of 170 million yuan, an increase of 36.30% over the previous year

Chengyitong (300430.SZ) released its 2023 annual report. The company achieved operating income of 11 during the reporting period...

Zhitong FinanceApr 21 05:23 ET

Chengyitong (300430.SZ): Long Zhijie has now developed products such as transcranial magnetic navigation systems and magnetic brain stimulation therapy devices

Gelonghui, April 12, 丨 Chengyitong (300430.SZ) said on the investor interactive platform that the company has always attached great importance to technical reserves and product development in brain science. The rehabilitation industry is one of the most successful and extensive fields of application of related technology. Long Zhijie began exploring related technologies in 2020. Currently, it has developed products such as transcranial magnetic navigation systems and magnetic brain stimulation therapy devices, and established Beijing Brain Link Technology Co., Ltd. on March 28, 2024. In the future, it will rely on Brain Connect Technology's platform to further explore brain-computer interface related technology and carry out related technical research and product development work, for big

Gelonghui FinanceApr 12 03:50 ET